Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Maintenance in SCLC
NCT03780283Phase 2Unknown
- Sponsor
- People's Hospital of Shijiazhuang
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in small cell lung cancer (SCLC), sponsored by People's Hospital of Shijiazhuang. Status: unknown.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03780283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780283.